Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | Biomarkers of response to OMO-103, a novel MYC inhibitor

Laura Soucek • 16 Apr 2023
AACR 2023
General OMO-103

Laura Soucek, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, presents biomarker results from a Phase I/II trial (NCT04808362) assessing OMO-103, a first-in-modality pan-MYC inhibitor, in patients with solid malignancies. Transcriptomic analysis of tissue samples and liquid biopsies enabled the detection of biomarkers relating to MYC inhibition as well as pharmacodynamic biomarkers. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Laura Soucek

0:57
The pharmacodynamics of the pan-MYC inhibitor OMO-103
Laura Soucek • 16 Apr 2023
1:04
What are the potential applications of MYC inhibition in oncology?
Laura Soucek • 16 Apr 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals